Valuation and Impairment Risk for Investment Securities
First written in FY2021. 3 of 7 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2023: 6 of 13 companies on the "Worse" side.
0 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「During the fiscal year, the company recognized an impairment loss of ¥87.94 million on securities (shares classified as other securities).」
Although the company continued to recognize impairment losses on investment securities, the amount decreased from ¥320.099 million in the previous fiscal year to ¥87.94 million. The risk has materialized, but the amount incurred has declined. - FY2024WorsenedAnnual report
「During the consolidated fiscal year, the company recognized an impairment loss of ¥320.099 million on securities (shares classified as other securities).」
Impairment losses on investment securities increased from ¥300 million in the previous fiscal year to ¥320.099 million, expanding the amount of valuation and impairment losses incurred. - FY2023MaterialisedAnnual report
「During the consolidated fiscal year, the company recognized an impairment loss of ¥300 million on securities (shares classified as other securities).」
The company had previously disclosed declines in the value of investee investments and impairment as potential risks, but recognized an impairment loss of ¥300 million on investment securities during the consolidated fiscal year. - FY2023-Q2RestatedAnnual report
「During the six-month period ended in the second quarter, there was no new business risk or material change in the business risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes to previously disclosed risks related to declines in the value of investment securities and impairment. - FY2023-Q1RestatedAnnual report
「During the three months ended 31 May 2024, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes to previously disclosed risks related to declines in the value of investment securities and impairment. - FY2022-Q3RestatedAnnual report
「During the nine-month period ended in the third quarter, there was no new business risk or material change in the business risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes to previously disclosed risks, including valuation and impairment risk for investment securities. - FY2021First statedAnnual report
「The business plans of investees are subject to uncertainty. If their fair values decline significantly, impairment losses on investment securities may need to be recognized, which could have a material impact on the consolidated financial statements for the following consolidated fiscal year.」
The company has for the first time disclosed the risk that the valuation of investments in unlisted shares and investment business partnerships may decline, requiring impairment treatment, depending on the investee's market environment, performance and progress against its business plan.